Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Semapimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 1/20 | 0.63 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.63 |
| ▸ | AURKA | O14965 | 1/20 | 0.63 |
| ▸ | CHUK | O15111 | 1/20 | 0.63 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.63 |
| ▸ | JAK2 | O60674 | 1/20 | 0.63 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.63 |
| ▸ | PAK4 | O96013 | 1/20 | 0.63 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.63 |
| ▸ | CDK1 | P06493 | 1/20 | 0.63 |
| ▸ | PIM1 | P11309 | 1/20 | 0.63 |
| ▸ | PRKACA | P17612 | 1/20 | 0.63 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.63 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.63 |
| ▸ | CDK2 | P24941 | 1/20 | 0.63 |
| ▸ | MARK3 | P27448 | 1/20 | 0.63 |
| ▸ | AKT1 | P31749 | 1/20 | 0.63 |
| ▸ | AKT2 | P31751 | 1/20 | 0.63 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.63 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Semapimod SCHEMBL6150586 | 1.00 | PLK4 (0.63) | PLK4CHEK1AURKACHUKDAPK3 | |
| SCHEMBL11989635 | 1.00 | PLK4 (0.63) | PLK4CHEK1AURKACHUKDAPK3 | |
| Semapimod SCHEMBL6356573 | 0.99 | PLK4 (0.62) | PLK4CHEK1AURKACHUKDAPK3 | |
| Semapimod SCHEMBL6356576 | 0.99 | PLK4 (0.62) | PLK4CHEK1AURKACHUKDAPK3 | |
| SCHEMBL11989623 | 0.99 | PLK4 (0.64) | PLK4CHEK1AURKACHUKDAPK3 | |
| SCHEMBL11989630 | 0.96 | PLK4 (0.59) | PLK4CHEK1AURKACHUKDAPK3 | |
| SCHEMBL11989628 | 0.96 | PLK4 (0.59) | PLK4CHEK1AURKACHUKDAPK3 | |
| SCHEMBL13248987 | 0.96 | PLK4 (0.59) | PLK4CHEK1AURKACHUKDAPK3 | |
| SCHEMBL24681759 | 0.95 | PLK4 (0.58) | PLK4CHEK1AURKACHUKDAPK3 | |
| SCHEMBL16207216 | 0.95 | PLK4 (0.58) | PLK4CHEK1AURKACHUKDAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 543 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4058037-B1 | FIBROBLAST-BASED THERAPY FOR TREATMENT AND PREVENTION OF STROKE | SPINALCYTE LLC (US) | 2026-01-28 | — | — | EP | claimed |
| US-20260007778-A1 | METHODS FOR TREATING AND DIAGNOSING BLINDING EYE DISEASES | TRANSLATUM MEDICUS INC (CA) | 2026-01-08 | — | — | US | claimed |
| EP-4674954-A1 | TUMOR INFILTRATING LYMPHOCYTE EXPRESSING MEMBRANE-BOUND CYTOKINE | Shanghai Juncell Therapeutics Co., Ltd. (CN) | 2026-01-07 | — | — | EP | claimed |
| EP-4662203-A1 | BINDARIT CONJUGATES, COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES OR DISORDERS | Translatum Medicus Inc. (CA) | 2025-12-17 | — | — | EP | claimed |
| US-20250177565-A1 | METHODS AND MATERIALS FOR INHIBITING/PREVENTING THE TRAFFICKING OF MONOCYTES TO THE CENTRAL NERVOUS SYSTEM | DARTMOUTH COLLEGE (US) | 2025-06-05 | — | — | US | claimed |
| US-12138274-B2 | Compositions and methods for the treatment of peripheral artery disease and cardiopulmonary diseases | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2024-11-12 | — | — | US | claimed |
| US-20240325538-A1 | TUMOR INFILTRATION LYMPHOCYTE CULTURE MEDIUM AND APPLICATION THEREOF | SHANGHAI JUNCELL THERAPEUTICS CO., LTD. (CN) | 2024-10-03 | — | — | US | claimed |
| US-20240316055-A1 | METHODS FOR TREATING LEIGH SYNDROME | DBCC RES LLC (US) | 2024-09-26 | — | — | US | claimed |
| WO-2024179465-A1 | TUMOR INFILTRATING LYMPHOCYTE EXPRESSING MEMBRANE-BOUND CYTOKINE | 上海君赛生物科技有限公司 | 2024-09-06 | — | — | WO | claimed |
| WO-2024165925-A1 | BINDARIT CONJUGATES, COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES OR DISORDERS | Translatum Medicus Inc. (CA) | 2024-08-15 | — | — | WO | claimed |
| CN-113133995-B | Application of inhibitor CNI-1493 in porcine reproductive and respiratory syndrome | 河南牧业经济学院 | 2022-09-02 | — | — | CN | claimed |
| US-20220275062-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | ORPH PHARMA IP COMPANY LIMITED (GB) | 2022-09-01 | — | — | US | claimed |
| WO-2022111573-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING CELL KILLING, AND USE THEREOF | 上海君赛生物科技有限公司 | 2022-06-02 | — | — | WO | claimed |
| WO-2022111571-A1 | TUMOR INFILTRATION LYMPHOCYTE CULTURE MEDIUM AND APPLICATION THEREOF | 上海君赛生物科技有限公司 | 2022-06-02 | — | — | WO | claimed |
| EP-3277719-B1 | POLYPEPTIDES | SORRISO PHARMACEUTICALS INC (US) | 2022-03-16 | — | — | EP | claimed |
| WO-2022040799-A1 | ANTIMICROBIAL COMPOSITION | GP TECH INOVASYON TEKNOLOJI VE ARASTIRMA A.S (TR) | 2022-03-03 | — | — | WO | claimed |
| WO-2022034031-A1 | METHODS OF PREVENTING OR TREATING COVID-19 AND RELATED VIRAL DISEASES OR DISORDERS | KINARUS AG (CH) | 2022-02-17 | — | — | WO | claimed |
| EP-3553169-B1 | NORMALIZATION OF CULTURE OF CORNEAL ENDOTHELIAL CELLS | KYOTO PREFECTURAL PUBLIC UNIV CORP (JP) | 2021-11-03 | — | — | EP | claimed |
| US-20160331736-A1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | THE DOSHISHA (JP) | 2016-11-17 | — | — | US | claimed |
| EP-3069732-A1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | The Doshisha (JP) | 2016-09-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007778-A1 | METHODS FOR TREATING AND DIAGNOSING BLINDING EYE DISEASES | AGER, ALDH1A2, RBP1 | PLK4 4050/4885CHEK1 3914/4885AURKA 4797/4885 |
| US-20240316055-A1 | METHODS FOR TREATING LEIGH SYNDROME | ECHS1, GLS2, OAT | PLK4 3029/4885CHEK1 3960/4885AURKA 3908/4885 |
| US-20220275062-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | CXCL10, MAPK10, CCL11 | PLK4 1107/4885CHEK1 1050/4885AURKA 2434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.